All Drug Development articles
-
NewsHow researchers are recreating the human heart in the lab
Many promising therapies fail because preclinical models do not fully capture the complexity of the human heart. A new review explores how 3D cardiac constructs could improve disease modelling, drug screening and safety assessment.
-
NewsAI identifies 23 antiviral candidates for Bundibugyo Ebola strain
US researchers have deployed artificial intelligence and molecular docking software to identify 23 antiviral compounds with potential activity against Bundibugyo Ebolavirus, as the rare strain continues to spread in the Democratic Republic of Congo with a fatality rate approaching 40 percent.
-
NewsCardiac organoids repair heart attack damage in preclinical study
Researchers have developed a scalable bioreactor-based system to produce cardiac organoids that successfully integrated into damaged heart tissue in porcine models of myocardial infarction, improving cardiac function and reducing scar formation without triggering arrhythmias.
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
NewsISSCR consortium submits recommendations on NAMs to FDA
The ISSCR Consortium on Advanced Stem Cell-Based Models is calling for greater flexibilty from the FDA to accomodate rapidly changing technologies like stem cell-derived systems, organoids and computational approaches.
-
ArticleWhen antibiotics are not enough: the case for immune-engaging therapies
As antimicrobial resistance grows and patient populations become more complex, the limitations of antibiotics are becoming harder to ignore. Dr Helen Bright, CSO at Centauri Therapeutics, discusses a new approach that targets both the pathogen and the host.
-
NewsC-Path launches coalition to advance human-relevant drug discovery
The New Approach Methodologies Developer Coalition brings together technology developers, pharmaceutical companies and regulators in a precompetitive initiative to establish qualification standards for complex in vitro models, microphysiological systems and related human-relevant technologies.
-
NewsNew study indentifies Golgi apparatus proteins as cancer growth drivers
Researchers at the Harrington Discovery Institute have identified cellular mechanisms involving Golgi apparatus proteins that drive cancer progression by trafficking growth factor receptors to cell surfaces.
-
ArticleAACR 2026 part 1: AI design, precision biology and the next wave of oncology innovation
At AACR 2026, industry leaders discussed how oncology R&D is moving beyond isolated technological advances towards integrated discovery systems.
-
NewsCircio’s circular RNA platform shows 40-fold gene expression boost
Circio Holding has presented preclinical data at ASGCT demonstrating that its circVec circular RNA platform achieved up to 40-fold greater gene expression in cardiac tissue and 50-fold in ocular tissue compared with conventional AAV gene therapy approaches, potentially enabling significant dose reductions and improved safety profiles.
-
ArticleWomen in STEM: resilience and leadership in rare disease research
Rare neurological diseases remain one of the most challenging areas in drug discovery, with many patients still lacking treatment options. Dr Nitza Thomasson discusses returning to Servier to lead its rare neurology therapeutic area and explains why resilience, curiosity and persistence are essential for those looking to build a meaningful career in STEM.
-
NewsRAGE receptor identified as key driver of age-related metastasis
Georgetown Lombardi researchers have identified RAGE, an inflammatory receptor, as a key mediator of age-related breast cancer metastasis.
-
NewsMYC protein found to repair DNA in cancer cells
Oregon Health & Science University researchers have identified a non-canonical function of the MYC oncoprotein in DNA damage repair, revealing how tumour cells survive chemotherapy-induced stress.
-
NewsMitochondrial fission activation offers new tool in fight against antibiotic resistance
Scientists at The University of Queensland have discovered that activating mitochondrial fission can enhance immune defences against antibiotic-resistant bacteria.
-
NewsCAR T cell therapy eliminates glioblastoma tumours in preclinical study
A next-generation CAR T cell immunotherapy targeting the urokinase receptor has eliminated treatment-resistant glioblastoma tumours in preclinical models.
-
NewsAI system transforms weak antibiotics into powerful treatments
University of Pennsylvania researchers have developed ApexGO, an AI system that refines imperfect antibiotic candidates through calculated modifications rather than database screening.
-
NewsNew malaria drug T111 targets all parasite stages in single treatment
A novel compound developed over 15 years of research has demonstrated unprecedented activity against liver, blood and sexual stages of Plasmodium parasites, possibly positioning it as a potential cure for malaria.
-
NewsAI system reduces animal testing in drug discovery by 50 percent
German researchers have developed genESOM, a generative AI system that could reduce animal numbers in preclinical drug testing by 30 to 50 percent.
-
NewsASGCT 2026 Annual Meeting opens in Boston this week
The American Society of Gene & Cell Therapy’s 2026 Annual Meeting opens in Boston on 11 May, bringing together thousands of researchers, clinicians and industry leaders for five days of scientific programming.
-
NewsOpenBind launches AI model to accelerate drug discovery
Diamond Light Source has launched OpenBind v1, an open-access AI model and dataset designed to address critical data shortages in drug discovery by providing standardised protein-drug binding measurements at atomic resolution.